echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > In 2024, the market size of autoimmune drugs may reach nearly 50 billion yuan

    In 2024, the market size of autoimmune drugs may reach nearly 50 billion yuan

    • Last Update: 2022-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
     Autoimmune diseases are diseases in which the immune system mounts an immune response against the body's own normal components and damages the organs and tissues
    At present, there are about 100 different types of autoimmune diseases, the common ones are rheumatoid arthritis, ankylosing spondylitis, psoriasis and so on

    With the improvement of residents' disposable income and the advancement of medical technology, the market demand for autoimmune disease treatment drugs is showing a rapid growth trend in recent years

    A market research report shows that in 2019, the sales of autoimmune disease drugs in China has grown to 15.
    8 billion yuan

    It is estimated that by 2024, sales of autoimmune disease drugs are expected to rise by 46.
    2 billion yuan

    Notably, as the market continues to expand

    At present, more and more pharmaceutical companies have begun to increase their layout in this field

    It is understood that the current global pharmaceutical giants are almost all deployed in the field of autoimmunity.
    The prominent ones are Pfizer, Novartis, Johnson & Johnson, and AbbVie.
    There are more than 18 products under development or on the market in the pipelines of the above companies

    On the whole, the main targets of most drugs have been tumor necrosis factor (TNF) and interleukin, and the development targets of small molecule compounds are mostly tyrosine kinase inhibitors, such as Janus kinase, (JAK) and Bruton tyrosine.
    Kinase (BTK)

    Of course, in the face of the huge market, domestic enterprises will not miss it

    On February 23, Huadong Medicine announced that its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co.
    , Ltd.
    (“Zhongmei Huadong”) and Kiniksa Pharmaceuticals (UK), Ltd.
    (hereinafter referred to as Kiniksa) signed an exclusive product license agreement.

    The announcement shows that Sino-US Huadong has obtained the exclusive licenses of two autoimmune global innovative products Arcalyst and Mavrilimumab from Kiniksa in 24 Asia-Pacific countries and regions (excluding Japan) including China, South Korea, Australia, New Zealand and India, including development, registration and commercial Equity

    MidAmerican East will pay Kiniksa an upfront payment of $22 million, development, registration and sales milestone payments of up to $640 million, as well as tiered double-digit royalties on net sales

    In addition to Huadong Medicine, many domestic companies have increased their layout in the field of self-freedom in recent years, and Sunshine Guojian has performed very well

    Incomplete statistics show that as of November 2021, in its R&D pipeline, in addition to the marketed TNF-α inhibitor Yisaipu, there are 5 self-immune drugs under development, 3 of which have completed clinical phase I trials.
    , 1 is in Phase I clinical trials, and 1 is in the pre-IND stage

    Among them, SSGJ-608 is an inhibitor targeting IL-17A, and the declared indication is moderate to severe plaque psoriasis

    Data show that the incidence of psoriasis in China is about 0.
    47%, with nearly 6.
    5 million patients, of which 57.
    3% are moderate to severe patients

    The industry predicts that if the drug can be successfully launched, the market space will be very broad

    In general, with the improvement of autoimmune disease diagnosis in the future, the large number of autoimmune disease patients and the promotion of policies, China's autoimmune disease drug market will continue to maintain rapid growth

    In this context, pharmaceutical companies and capital will continue to enter the market to promote the accelerated approval and marketing of domestic autoimmune disease drugs, bringing more new drug options to relevant domestic patients

    Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.